Clinical Trials Update: July 12, 2006
Multiple Sclerosis Diabetes - Type 2 Acute Myelogenous Leukemia (AML)
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Dr. Nancy Sicotte at UCLA is conducting a study to evaluate MS activity using brain scans (MRI) in women with MS after delivering a baby.
If you are pregnant, diagnosed with MS, and able to undergo MRIs, you may qualify for this study. There will be MRIs and blood drawn at months 3, 6, and 12 postpartum. There will be payment for your participation.
The research site is in Los Angeles.
Diabetes - Type 2
The purpose of this study is to determine the safety and efficacy of a six-month treatment period of an oral study drug taken daily by patients with type 2 diabetes and persistent albuminuria (presence of protein in urine).
Those eligible to participate should be age 31 or older diagnosed with type 2 diabetes after age 30, who had no requirement for insulin in the first year of diagnosis, and have a BMI at or below 40 may be eligible.
The research site is in various cities across Canada.
Acute Myelogenous Leukemia (AML)
North Shore University Hospital in New York is recruiting patients with secondary acute myeloid leukemia to participate in a clinical study to test the effectiveness of an experimental drug used with an already approved chemotherapy in driving the cancer into remission.
You may be included in this study if you have been diagnosed with secondary AML that developed following prior treatments of chemotherapy or radiotherapy. You may also qualify if secondary AML developed following your diagnosis of myelodysplastic syndrome (MDS) at least 3 months before study entry, are at least 18, and have adequate heart, liver, and kidney function.
Volunteers will not be eligible to participate in this study if they have clinical active central nervous system leukemia, are HIV positive, have Hepatitis B or C or other active liver disease, or have had prior therapy for AML.
The research site is in Lake Success, N.Y.
Copyright 2006 Thomson CenterWatch. All rights reserved.